Near Term Growth Opportunities
BackgroundClient's drug was 4th entry in very competitive class. It had meaningful side effect advantages versus entrenched competitors, and had a very successful launch. It was now entering its third year in the Rx market, with a pipeline of new indications planned. However, there was significant pressure from management to accelerate growth in the next 3 years.
"Over-delivered. We have an excited team with an abundance of things to work with. Unexpected that all this could come from better integrating the way we look at things."